DSM Sinochem Pharmaceuticals
DSM Sinochem Pharmaceuticals launches Caspofungin finished dosage, its first foray into the anti-fungals portfolio
Rijswijk, the Netherlands, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Sustaining earlier momentum from its successful launches of generic versions of both Rosuvastatin and Atorvastatin earlier in 2018, DSM Sinochem Pharmaceuticals (DSP) has now introduced its generic Caspofungin anti-fungal drug product in the United Kingdom. Additional markets within the EU are scheduled to follow later in the year.
Caspofungin is primarily used in the treatment of invasive candidiasis and aspergillosis, along with other fungal infections. DSP’s generic version is a concentrate powder for infusion solutions, produced in the form of single use vials.
Ongoing portfolio expansion
With the launch now of its first anti-fungal finished dosage formulation, DSP is actively expanding its drug product portfolio, realizing its aspiration of becoming a full-service generics pharmaceutical company. DSP can now offer finished drug products in statins, anti-fungals and antibiotics across its global network.
Business Unit Director for Drug Products at DSP, Lucas Wiarda stated : “With our third launch of a finished dosage drug product in 2018, I am extremely proud of the team at DSP and the successes we’ve enjoyed this year. Caspofungin is the ideal complement to our product line, which helps to move DSP forward in our goal of producing a full range of finished dosage products for our Active Pharmaceutical Ingredients (APIs). Additionally, with Caspofungin we have a global dossier, allowing us worldwide access for production and sale in the coming years.”
With the introduction of Caspofungin finished dosage formulation into the marketplace, DSP continues to deliver on its brand promise to customers, with Quality via world-class, differentiated active pharmaceutical ingredients, Reliability through a secure supply chain for producing a finished dosage product, and Sustainability at the forefront of its drug product production, using patented enzymatic technology which ensures an unmatched eco-friendly production process.
DSP holds an electronic Common Technical Document (eCTD) dossier for Caspofungin finished dosage formulations (in 50 and 70 mg vials) requiring constant refrigerated storage between 2 and 8 degrees Celsius.
About DSM Sinochem Pharmaceuticals
DSM Sinochem Pharmaceuticals (DSP) is the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP develops, produces and sells intermediates, active pharmaceutical ingredients and drug products. Our employees worldwide work together to deliver cutting-edge generics solutions that help to keep customers ahead of the competition.
Headquartered in Singapore, the group has manufacturing sites and sales offices in China, India, Egypt, the Netherlands, Spain, the USA and Mexico. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company active in health, nutrition and materials, and Sinochem Group, a Fortune 500 enterprise.
For more information please visit www.dsm-sinochem.com or contact DSM Sinochem Pharmaceuticals Corporate Communications, Geoff Vokes, Senior External Communications Manager. E-Mail: email@example.com
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Globenewswire
ADC Therapeutics SA16.1.2019 07:01 | Pressemeddelelse
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors
CGAP15.1.2019 14:10 | Pressemeddelelse
Credit Suisse Partners with CGAP on Digital Finance to Catalyze Delivery of Energy, Water and other Services to Low Income People
TrueCommerce15.1.2019 14:01 | Pressemeddelelse
TrueCommerce Recognized as a Leader in IDC MarketScape for Worldwide Multi-Enterprise Supply Chain Commerce Network
Appian Corporation15.1.2019 13:32 | Pressemeddelelse
UnionBank Launches First Fully Digital Branch in the Philippines
Magna International Inc.15.1.2019 11:01 | Pressemeddelelse
Magna Announces Outlook
PSAV14.1.2019 18:01 | Pressemeddelelse
PSAV® and The Freeman Company Announce Purchase Agreement for PSAV to Acquire Encore Event Technologies
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum